New Combination Therapy Effective Against Mantle Cell Lymphoma
Research from the University of Texas MD Anderson Cancer Center demonstrates that combining bortezomib (BTZ), a chemotherapy drug, with atiprimod (ATI), a drug that prevents cancer cells from multiplying, delays tumor growth and prolongs survival for mantle cell lymphoma (MCL). A rare form of non-Hodgkin's lymphoma (NHL), MCL is aggressive…






